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ABSTRACT:: A previous genome-wide association study
in asthma revealed putative associations that merit fur-
ther investigation. In this study, the genome-wide sig-
niﬁcant associations of SNPs at the 5% false discov-
ery rate were examined in independent groups of severe
asthmatics. The panel consisted of 397 severe asthmatic
adults, 116 severe asthmatic children, and a collection of
207 family-trios with an asthmatic proband. Three SNPs
in the PDCD4 gene (rs6585018:G>A, rs1322997:C>A,
and rs34104444:G>A) were signiﬁcantly associated with
severe childhood asthma (P values: 0.003, 0.002, 0.004)
and total immunoglobulin E (IgE) levels (P values:
0.034, 0.041, 0.052). In an independent group of 234
asthmatic children and 652 controls, PDCD4 SNPs
rs1407696:T>G and rs11195360:T>C were associated
with total IgE levels (P values: 0.006, 0.014). In silico
analysis of PDCD4 locus showed that rs6585018:G>A
had the potential to affect MYB transcription factor bind-
ing, shown to act as a PDCD4-transcription inducer. Elec-
tromobility shift assays and reporter assays revealed that
rs6585018:G>A alters MYB binding thereby inﬂuencing
the expression of PDCD4. SNPs within MYB itself confer
susceptibility to eosinophilia and asthma. Our association
between a variant MYB binding site in PDCD4 and the
severest form of childhood asthma therefore suggests that
PDCD4 is a novel molecule of importance to asthmatic
inﬂammatory responses.
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Introduction
Asthmaisachronicinﬂammatorydiseaseofthelungsinvolvinga
number of physiological mechanisms. It affects approximately 300
million people worldwide and is the single most common respi-
ratory disease of childhood [Masoli et al., 2004]. Because of the
frequent hospital admissions and the regular use of antiasthma
treatments, approximately 80% of the entire ﬁnancial burden for
the disease is attributable to the 20% of patients with the severest,
steroid resistant form of the disease [Smith et al., 1997].
During the last decade, genome-wide association studies
(GWAS) on asthma phenotypes have highlighted novel putative
pathways adding novel targets to the list of asthma-associated loci
[Zhang et al., 2012]. It is estimated, however, that the largest part of
the heritability of complex diseases remains unidentiﬁed [Manolio
et al., 2009]. Some of the proposed explanations for the “missing
heritability” include the small effect size of numerous variants not
reaching a genome-wide signiﬁcant association at the large GWAS,
the existence of rare variants not present in commercial genotyping
arrays and the heterogeneity of the investigated disease phenotypes
[Gibson, 2010; Manolio et al., 2009; Yang et al., 2010]. In addition,
thereareonlyasmallnumberofstudiesprovidingafunctionaleval-
uationoftheGWASﬁndings[Lluisetal.,2011;Verlaanetal.,2009].
Studiescombininggeneticanalysisinhomogenouspopulationsand
incorporating functional data could also evaluate or propose novel
unexplored candidate loci assessing simultaneously a well-deﬁned
phenotype of the disease [Cusanovich et al., 2012; Tantisira et al.,
2011].
Previously,aGWASforasthmaidentiﬁedalocusonchromosome
17q21,containingtheORMDL3(MIM#610075)andGSDMAgenes
(MIM#611218),tobehighlysigniﬁcantlyassociatedwithchildhood
asthma [Moffatt et al., 2007]. This association has now been widely
replicated by a number of independent studies [Binia et al., 2011;
Bouzigon et al., 2008; Galanter et al., 2008; Madore et al., 2008;
Moffatt et al., 2010; Tavendale et al., 2008]. On-going functional
studiesaimtoelucidatethebiologicalroleoftheseﬁndings[Breslow
et al., 2010; Cantero-Recasens et al., 2010].
C   2013 The Authors. ∗Human Mutation published by Wiley Periodicals, Inc.
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original work is properly cited.Figure1. Theoutlineofthestudyplan(N:number;FDR:falsediscov-
ery rate; B58C: British 1958 Birth Cohort study).
In addition to the 17q21 locus exceeding the genome-wide sig-
niﬁcance level (at 1% false discovery rate, FDR), genetic markers
showed suggestive results at 5% FDR [Moffatt et al., 2007]. Evi-
dently a great proportion of these represent false positive results
[McCarthy et al., 2008]; however some of these hits could point to
further asthma-associated loci with a smaller effect not captured by
the GWAS. This study aimed to further investigate these underlying
associations in cases of child and adult severe asthma followed by
ﬁne-mapping and functional assays (Fig. 1 ).
Material and Methods
Subjects, Genotyping, and Imputation
Subjects from the United Kingdom
Cases, adults, and children all white with British ancestry were
recruited from severe asthma clinics based within the UK. For the
severe asthmatic adults, asthma was physician-diagnosed and de-
ﬁned as severe according to the American Thoracic Society (ATS)
criteria (2000). For the child cases, the Global Initiative for Asthma
(GINA)criteriawerefollowed[Bousquet,2000]withsevereasthma
deﬁned as Step 4 severe/persistent asthma which includes patients
with continuous symptoms during the day, frequent during the
night and Forced Expiratory Volume in 1 sec (FEV1)</ = 60%.
Mild asthmatic group included young adults and children (Age:
mean[standarddeviation] =29.49[8.10]),corticosteroid-naive,re-
ceiving treatment with only inhaled β2-agonists in an intermittent
basis. Additionally, a panel of 207 families administered a stan-
dard questionnaire (based on the ATS and International Study of
Asthma and Allergies in Childhood, ISAAC questionnaires) and re-
cruited through a proband with severe asthma (Step III asthma or
worse) according to the British Thoracic Society guidelines were
included in the study [Moffatt et al., 2007]. Phenotypic charac-
terization of the cases and controls included detailed clinical data,
lung function tests, bronchial hyperresponsiveness, total IgE and
blood eosinophils counts. Three hundred and ninety seven se-
vere asthmatic adults, 111 mild adult asthmatics and 116 severe
asthmatic children were genotyped for the selected SNPs. DNA
was extracted from whole blood samples using the Wizard R   Ge-
nomic DNA Puriﬁcation Kit (Promega; http://www.promega.com)
and from saliva using the Oragene R  ·DNA collection system
(DNA Genotek, http://www.dnagenotek.com). DNA samples were
quantiﬁed using NanoDrop R   ND-1000 UV-Vis Spectrophotome-
ter. TaqMan R   SNP Genotyping Assays (Applied Biosystems;
http://www.appliedbiosystems.com, 7300 Real-Time PCR System)
were used for genotyping (assay details available upon request).
Only for SNP rs1322997:C>A, genotyping data from 1,480 asthma-
free healthy controls from the British 1958 Birth Cohort study
(http://www.b58cgene.sgul.ac.uk)wereavailableandtheywereused
as controls compared with severe asthmatic children to conﬁrm the
genetic associations. No descriptive data were available from the
British 1958 Birth Cohort study.
Subjects from Germany
Thedatasetconsistingoftwodistinctcohortshasbeenpreviously
described [Moffatt et al., 2007]. Asthma cases were recruited from
the Multicentre Asthma Genetics In Childhood Study (MAGICS),
whereassubjectsfromtheInternationalStudyofAsthmaandAllergy
in Childhood, phase II (ISAAC II) [Weiland et al., 1999] served
as controls. Details of the recruitment, chip-genotyping (Illumina
HumanHap300)anddeﬁnitionofphenotypeshavebeenpreviously
described [Michel et al., 2010; Toncheva et al., 2012]. To select the
severe asthmatics from the initial cohort we restricted the analysis
to those asthmatics that reported at least one (Severe Asthma 1,
N = 234) or at least four (Severe Asthma 2, N = 104) hospital visit
duetoasthmawithinthelast12monthsbeforerecruitment.Control
subjects (N = 652) were negative for asthma. Total serum IgE levels
were measured and the log-transformed values were used for the
association analysis.
Study genotypes were imputed using the current two stage
approach, separating phasing of study data and the subsequent
imputation [Howie et al., 2012]. First prephasing of the study
genotypes was done with MaCH [Li et al., 2010]. Second minimac
[Howie et al., 2012] was used with the recommended settings
[http://genome.sph.umich.edu/wiki/Minimac:_GIANT_1000_Gen
omes_Imputation_Cookbook] utilizing the 1000G Phase I Inte-
grated Release Version 3 Haplotypes [http://www.sph.umich.edu/
csg/abecasis/MaCH/download/1000G.2012–03–14.html] as refere-
nce panel.
Statistical Analysis
Deviation from Hardy–Weinberg equilibrium was calculated
for the allele frequencies for both cases and controls by a χ2 test.
SNPs with allele frequencies presenting a signiﬁcant deviation
from Hardy–Weinberg equilibrium were excluded. For the SNPs
not previously part of the GWAS SNP chip [Moffatt et al., 2007],
a family-based test (the Transmission Disequilibrium Test, TDT)
was performed for the family panel in R statistical package. Allele
frequencies were compared between severe asthmatics (cases) and
nonasthmatic subjects (controls) by Fisher’s exact test and odds
ratios (OR) calculated for minor alleles. The same comparisons
wereperformedforsevereasthmatics(cases)versusmildasthmatics
(controls). At each stage of the analysis, the 5% FDR adjustments
for multiple testing were calculated at Qvalue software in R
statistical package [Storey and Tibshirani, 2003]. For quantitative
traits (total IgE levels, blood eosinophils counts and FEV1%)
and SNP associations, an analysis of variance was performed
using log-transformed variables to achieve a normal distribution.
Haplotype analysis was carried out for the cases and the controls
in the severe asthmatic children versus nonasthmatic children
study design using Haploview 3.3 [Barrett et al., 2005]. Plots were
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Germany, additive genetic effects were modeled using logistic or
linear (serum IgE levels) regression implemented in the ProbABEL
software package [http://www.genabel.org; Aulchenko et al., 2010].
Fine Mapping of the PDCD4 Region
The area including the SNPs on PDCD4 (NM 145341.3) geno-
typed in the original GWAS [Moffatt et al., 2007] was exam-
ined and tagging SNPs covering variations not included in the
arrays used in the original GWAS were selected using the pair-
wise tagging algorithm in Haploview 3.3 (r2 > 0.8) [Barrett
et al., 2005]. Linkage disequilibrium (LD) of the area was as-
sessed using the HapMap CEU genotype data (version 2, Phase
1 and 2, http://hapmap.ncbi.nlm.nih.gov/). Genome browsers
http://www.ensembl.org/index.html and http://genome.ucsc.edu/
were also used to visualize the LD and the regulatory elements
as reported from the Encyclopedia of DNA Elements (ENCODE)
project spanning the gene region [Kuhn et al., 2012]. Three ad-
ditional tagging SNPs and one coding SNP in the PDCD4 (MIM
#608610) area (rs1322997:C>A, rs11195360:T>C, rs1407696:T>G,
and rs34104444:G>A) were selected to be genotyped in the ﬁne
mapping study (Fig. 2). In addition, the putative promoter of
PDCD4 was sequenced for the identiﬁcation of potentially novel
polymorphisms in 24 samples with known rs6585018:G>A geno-
types (14 AA and 10 GA). Two sets of primers were designed (In-
vitrogen; http://www.invitrogen.com, sequences available upon re-
quest) to amplify 2 promoter regions, 112,621,625 to 112,622,006
and112,622,164to112,622,604(NCBIBuild36.1).Thesequencing
resultswereassembledalignedandvisualizedusingtheCodonCode
Aligner software Version 2.06 (http://www.codoncode.com/).
Cell culture, protein extraction, and electromobility
shift assays
To obtain protein extracts for the electromobility shift assays
(EMSA) experiment, Jurkat (T cells), Daudi (B cells) and A549
(Airway epithelial cells) were purchased from the American Type
Culture Collection (http://www.atcc.org). Jurkat, A549 and Daudi
celllineswereculturedinstandardmediaat37◦Cand5%CO 2.Cell
lineswerenotallowedtoexceedpassage5or6beforeproteinextrac-
tions were prepared using a modiﬁed Schreiber protocol [Schreiber
et al., 1989]. Yield of protein obtained was quantiﬁed using the
Bradfordassay[Bradford,1976].TheregionscontainingthePDCD4
polymorphisms were analyzed for transcription factor binding sites
using TFSEARCH [Heinemeyer et al., 1998] and MatInspector
[Cartharius et al., 2005]. The expression of the protein in Jurkat,
in A549 and Daudi cell lines was conﬁrmed by Western blots (data
not shown). For EMSA on rs6585018:G>A, sense and antisense
single-stranded oligonucleotides for the two alleles were designed
(oligonucleotides available upon request) and synthesized (Invitro-
gen;http://www.invitrogen.com).MYBconsensusbindingsequence
(5 -YAAC[GT]G-3 ) oligonucleotides were used as a positive con-
trol. The oligonucleotides were annealed to form the SNP-speciﬁc
probes and labeled by Klenow fragment (Invitrogen) with α-32P
CTP(PerkinElmer R  ;http://www.perkinelmer.com)[Hackingetal.,
2004]. EMSA binding reactions were set up containing 4–10 μgo f
nuclearextracts,2–3μlofradiolabeledprobe,12mMHEPESbuffer
(pH 7.8), 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 12% glycerol,
and 0.5 μg poly(dA-dT) (Sigma; http://www.sigmaaldrich.com) in
a ﬁnal reaction volume of 15 μl. Competition assays were included
adding unlabeled probe 15 times (15×) and 60 times (60×)o ft h e
amountofthelabeledprobe.Forsupershiftassays,0.3ngofantibody
was added before incubation. The antibodies used were anti-MYB
and anti-SRY (Abcam, http://www.abcam.com). After incubation,
the reactions were run on 6% nondenaturing polyacrylamide gels
at 4◦C and 80–100 V, using 0.5× TBE running buffer. Kodak
X-OmatARﬁlmautoradiography(Sigma)wasusedtovisualizethe
results.
Constructs, transfections, reporter assays
pGL3.rs6585018+AandpGL3.rs6585018+Gconstructsweregen-
erated by amplifying a 219 bp sequence spanning rs6585018:G>A
(sequences available upon request) and cloning into a MluI-
BglII-digested pGL3-promoter vector (Promega) upstream of the
SV40 promoter. The constructs were veriﬁed by multiple diges-
tions and sequencing (data not shown). Nucleofector (Lonza;
http://www.lonza.com) and electroporation (Nucleofector R   II De-
vice) were used to transfect Jurkat cell lines with and without the
reporter gene constructs (triplicates done for each experiment) fol-
lowing the optimized manufacturer’s protocol for Jurkat cell lines
(ATCC). One million cells were transfected with 2 μgo ft o t a lD N A .
Vector pRL.TK was cotransfected to normalize for transfection ef-
ﬁciency. After 24 hr, cells were lysed and analyzed using the Dual-
LuciferaseReporterAssaykit(Promega)andaluminometerfollow-
ing the manufacturer’s protocol.
Results
Top Ten GWAS Hits Association Study
From the previous GWAS [Moffatt et al., 2007], the top ten hits
(at FDR) ≥ 5%) were selected, excluding the 17q21 region, for
genotyping in severe asthmatics (N = 513) and healthy controls
(N = 414) (Fig. 1, Table 1). Call rates and tests for deviation from
Hardy–WeinbergEquilibriumresultsforallSNPsshowedthat9out
of 10 SNPs passed the genotyping quality control (Table 2). SNP
rs1401107:C>T had a call rate <90% and was therefore excluded
from further analyses.
Analyses of severe asthmatics versus nonasthmatic controls re-
vealedthat1ofthe9locifromtheinitialGWASshowedevidenceof
associationinthisindependentgroupofcasesandcontrols.Wedis-
coveredasigniﬁcantassociationbetweenthemarkerrs6585018:G>A
and severe asthma (OR = 1.92, 95% Conﬁdence Interval, [95% CI]:
1.14–3.32andP =0.006)(Table2).Rs6585018:G>Aislocatedwithin
the predicted promoter of the Programmed Death Cell Domain
4 (PDCD4) gene. Taking into account the heterogeneity of the
phenotypes, childhood asthma cases and controls were separated
from adulthood asthma cases and controls to test the association
for rs6585018:G>A. The results showed that the association was
restricted to the childhood asthma group (OR = 2.91, 95% CI:
1.40–6.05, P = 0.003). Risk allele G was more frequent in the severe
asthmatic children group (0.11) compared with controls (0.04)
and also compared with the general European population (CEU:
HapMap, rs6585018:G>A, minor allele frequency [MAF]: 0.06;
http://www.ncbi.nlm.nih.gov/ and EUR: 1000 Genomes Project,
rs6585018:G>A, MAF: 0.05; http://www.1000genomes.org/)
(Table 3). No signiﬁcant associations were seen for severe asthmatic
adult patients (OR = 0.94, CI: 0.53–1.69, P = 0.48).
Fine Mapping on PDCD4 Region
To ﬁne-map the genetic association in detail, additional SNPs
were selected for genotyping (Fig. 2). First, resequencing of
HUMAN MUTATION, Vol. 34, No. 8, 1131–1139, 2013 1133Figure 2. The PDCD4 gene structure. Haplotype analysis results from the HapMap CEU genotype data (combined Phase I and II) are shown in a
color scale map plot expressing the r2 value for linkage disequilibrium (white: r2 = 0, black: r2 = 1). Underlined SNPs were included in the original
GWASstudy[Moffattetal.,2007].SNPsselectedinthepresentstudyareshowninaframebox.Thepromoterarea112,621,625to112,622,604;NCBI
36.1 (chr10:112,631,200 to 112,632,179; NCBI 37.3) sequenced in the ﬁne mapping study is indicated by the patterned box. The area was entered in
the Ensembl Genome Browser (http://www.ensembl.org/index.html) to identify putative regulatory elements in different cell lines (red/green lines:
predicted promoter transcription; purple lines: polymerase III-associated region; grey lines and black boxes: unidentiﬁed regulatory elements).
Table 1. Characteristics of the UK Sample Collections Included in the Study
Severe asthmatics Family trios (N = 207) dataset
Severe Severe B58C
asthmatic asthmatic Asthmatic Asthmatic Healthy Healthy Mild Healthy
adults children adults children adults children asthmatics controls
Number N = 397 N = 116 N = 119 N = 295 N = 269 N = 145 N = 111 N = 1480
Mean age (yr) (SD) 47.17 (13.85) 12.05 (2.80) 35 (10.26) 10 (3.15) 40.92 (8.09) 10.11 (3.58) 27.85 (5.74) –
Sex (F:M) 2:1 2:3 1:1 2:3 1:1 1:1 1:2
IgE (kU/l) (SD) 258.6 (464.9) 1204 (2829.6) 264.44 (465.8) 725.01 (1068) 123.14 (343.50) 241.39 (517.02) –
Eosinophils counts (109/l) (SD) – 0.64 (0.63) 0.32 (0.22) 0.69 (0.45) 0.22 (0.21) 0.40 (0.36) –
FEV1% 64.3 (19.6) 76.8 (18.49) – – – – 90.0 (13.2)
SD, standard deviation; F/M, female/male; IgE, immunoglobulin E; yr, years; l, Litre; FEV1%, forced expiratory volume in 1 sec; B58C, British 1958 Birth Cohort study.
the putative PDCD4 promoter in 24 individuals (of known
rs6585018:G>A genotypes) identiﬁed no additional novel SNPs
(sequence reads available upon request). In the next step, LD
analysis was conducted to identify tagging SNPs within the PDCD4
gene capturing polymorphisms not genotyped nor tagged in the
original GWAS, so that all polymorphisms spanning the entire
PDCD4 area are adequately captured by GWAS-genotyped SNPs
and those included in the present study (Fig. 2). The four SNPs
selected (Supp. Table S1) were genotyped in the severe asthmatic
children (N = 116). All PDCD4 SNPs, including rs6585018:G>A,
were further genotyped in the subjects from the family collection
panel that included both asthmatics (N = 414) and healthy controls
(N = 414), and mild asthmatic young adults and children (N = 111)
(Table 1). All SNP genotype frequencies were in Hardy-Weinberg
equilibrium as assessed by χ2 test (Supp. Table S1).
Comparing severe asthmatic children versus healthy con-
trols, in addition to rs6585018:G>A, SNPs rs34104444:G>A,a n d
rs1322997:C>A were signiﬁcantly associated with severe childhood
asthma (OR = 2.83 95% CI: 1.31–6.11, P = 0.004 and OR = 2.94
95% CI: 1.41–6.11, P = 0.002, respectively) (Table 3). When mild
asthmatic young adults were used as controls, stronger associations
were seen for all SNPs, with P values ranging from 0.001 to 0.003
(Table3).Usingdatafor1480asthma-freehealthycontrolsfromthe
British 1958 Birth Cohort study (http://www.b58cgene.sgul.ac.uk)
strongassociations(P =0.0001forrs1322997:C>A)wereseenforse-
vere asthmatic children (Table 3). The results remained signiﬁcant
when correction for multiple testing was conducted using a FDR
threshold of 5%.
The family dataset with a severe asthmatic proband, used in
the original GWAS (11) in which an asthma-association with
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Case–control analysis
MAF Minor versus major allele
SNP Ancestral> GWAS- Call success HWE χ2 Cases Controls
Mutant Chrom Gene log10(P)r a t e s P value (N = 513) (N = 414) OR (CI) P value
rs1401107:C>T 2 Intergenic 5.92 85% 0.07 NA
rs10270097:C>A 7 DGKI 5.24 96.3% 0.38 0.07 0.06 1.32 0.08
(0.88–1.98)
rs481297:T>C 18 ST8SIA5 5.09 95.2% 0.10 0.34 0.34 1.00 0.49
(0.78–1.28)
rs2243603:G>C 20 SIRPB1 4.33 95.9% 0.37 0.23 0.25 0.88 0.18
(0.67–1.16)
rs1356847:T>C 2 Intergenic 4.15 94.8% 0.98 0.43 0.31 1.06 0.32
(0.83–1.39)
rs12715305:C>G 3 DLEC1 4.03 96.3% 0.99 0.32 0.33 0.94 0.32
(0.74–1.21)
rs11097415:G>A 4 SHROOM3 4.01 98.3% 0.95 0.38 0.38 1.00 0.49
(0.78–1.26)
rs6656822:T>C 1 SLC19A2 4.00 91.5% 0.93 0.30 0.31 0.94 0.32
(0.72–1.22)
rs6585018:G>A 10 PDCD4 4.70 99.6% 0.95 0.05 0.03 1.92 0.006
(1.14–3.32)
rs248944:C>G 19 ZNF506 4.23 97.1% 0.97 0.36 0.38 0.91 0.17
(0.75–1.11)
Chrom, chromosome; HWE, Hardy–Weinberg Equilibrium; N, absolute number; MAF, minor allele frequency; NA, not analyzed; OR, odds ratio; CI, conﬁdence intervals;
DGKI, diacylglycerol kinase iota; ST8SIA5, ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 5; SIRPB1, signal-regulatory protein beta 1; DLEC1, deleted in lung and
esophageal cancer 1; SHROOM3, shroom family member 3; SLC19A2, solute carrier family 19 (thiamine transporter), member 2; PDCD4, programmed death cell domain 4;
ZNF506, zinc ﬁnger protein 506.
rs6585018:G>A was reported (TDT: P = 0.0002), also showed sig-
niﬁcant associations for asthma and SNPs rs1322997:C>A and
rs34104444:G>A (TDT: P = 0.0002 and P = 0.0009, respectively)
(Table 3). As seen in the severe asthmatic children group, the MAFs
of all PDCD4 SNPs were increased in the cases compared with con-
trolgroups(MAF∼0.07fortheasthmaticprobandscomparedwith
∼0.04 for the control group).
Total immunoglobulin E levels were higher for the children
carrying the asthma-associated variant G in rs6585018:G>A and
rs1322997:C>A, P = 0.034 and P = 0.041, respectively (Table 3 and
Supp.Fig.S1).Eosinophilscountsandlungfunctionmeasurements
(% Forced Expiratory Volume in 1 sec, FEV1%) did not differ be-
tween subjects carrying the alternate alleles for any of the examined
SNPs (data not shown).
The effect size of the association of rs6585018:G>A with asthma
was estimated at OR = 1.99 95% CI: 1.07–3.81, P = 0.02, when
combining all asthmatic children, severe and asthmatic probands
fromthefamilydataset(N =411)andcomparingthemwithhealthy
children (N = 145) (Supp. Table S2).
Haplotype analysis for the severe asthmatic and nonasthmatic
children showed that the region was in high LD with two LD blocks
present (Supp. Fig. S2). Signiﬁcantly associated with asthma SNPs
rs6585018:G>A,rs34104444:G>A,andrs1322997:C>Aarepartofthe
same LD block (Supp. Fig. S2).
Replication Study Results
PDCD4 SNPs rs1407696:T>G and rs11195360:T>C were shown
to be signiﬁcantly associated with IgE levels (P < 0.01 and P < 0.02,
respectively) in an independent group of asthmatic children and
controlsfromGermany(Supp.TableS3).Nosigniﬁcantassociations
were observed for any tested SNP with the asthmatic status. SNPs
rs1407696:T>G and rs11195360:T>C belong to a different LD block
compared with the SNPs demonstrating signiﬁcant associations in
the UK population (Supp. Fig. S2).
Functional Analysis of PDCD4 SNPs
Interrogation of transcriptome data previously generated from
lymphoblastoid cell lines [Dixon et al., 2007] (http://www.sph.
umich.edu/csg/liang/asthma) revealed that all three PDCD4 SNPs
rs1322997:C>A, rs6585018:G>A,a n drs34104444:G>A that had
shown associations with severe asthma were correlated with the
expression levels of PDCD4 (LOD scores 2.64, 2.43, and 2.59, re-
spectively) (Table 3). The association results between SNPs and
PDCD4 transcript levels are corrected for multiple testing adjusted
at a FDR threshold of 5%.
Examining the ENCODE data for the region chr10:112,630,451–
112,631,970 (GRCh37/hg19 assembly), the area including
rs6585018:G>A has been reported to be rich in active regulatory
elements, such as strong active enhancer regions, DNase I hyper-
sensitivity sites and histone modiﬁcations as predicted by integrat-
ing chromatin immunoprecipitation sequencing (ChIP-seq) data
[Dunham et al., 2012]. Transcription factor binding analysis re-
vealed that one out of ﬁve PDCD4 SNPs, rs6585018:G>A,h a dt h e
potential to disrupt the binding of the transcription factor MYB
(v-myb myeloblastosis viral oncogene homolog) (Supp. Table S4).
Anallele-speciﬁcbandformationwasfoundbyEMSAusingnuclear
extracts from Jurkat and A549 cell lines. Competition assays in Ju-
rkat(Fig.3)andA459cells(Supp.Fig.S3)revealedtheformationof
a protein–DNA complex speciﬁc for the A allele of rs6585018:G>A
and identical results were obtained using a probe containing the
MYB-consensus binding site (Supp. Fig. S4). This was further con-
ﬁrmed by supershift assays using anti-MYB in the reaction (Fig. 4)
aswellasassaysinwhichanonspeciﬁcantibodywasincludedinthe
reaction (anti-SRY) (Supp. Fig. S5). Repetition of both the nuclear
extractions and EMSA reactions gave identical results.
To conﬁrm the allele-speciﬁc effects of rs6585018:G>A polymor-
phism on promoter activity, two luciferase reporter constructs were
generated including the MYB binding sequence 5  of PDCD4 and
A/G at the rs6585018:G>A polymorphic site. After transient trans-
fection into Jurkat cell lines, the relative luciferase activity of the
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Figure 3. Competition assay for PDCD4 SNP rs6585018:G>A using
10 μg of Jurkat nuclear extract per reaction. Lanes 1 and 9 contain
only the hot probes rs6585018_A and rs6585018_G, respectively. Lanes
2–8 include the rs6585018_A hot probe and lanes 11–16 include the
rs6585018_G hot probe. Lanes 2 and 10 are reactions with the hot probe
and the extract only. Unlabeled probe in excess was added in the
competition assays (lanes 3–8 and 11–16) as follows: lanes 3 and 11—
15×andlanes4and12—60×ofcoldrs6585018_A,lanes5and13—15×
and lanes 6 and 14—60×of cold rs6585018_Gand lanes 7 and 15—15×
and lanes 8 and 16—60× of cold PDCD4_unsp (unspeciﬁc) probe.
pGL3.rs6585018+Atransfectedcellswasfoundtobeincreasedcom-
pared with pGL3.rs6585018+Gt r a n s f e c t e dc e l l s( P < 0.02) conﬁrm-
ing the ﬁndings from the EMSA experiments (Fig. 5).
Discussion
In this study, the ﬁndings of a GWAS in childhood asthma [Mof-
fattetal.,2007]wereinvestigatedinanindependentgroupofsevere
asthmatic children and adults from the UK. Studying individuals
with the severest form of asthma is of particular importance be-
cause of the high clinical costs associated with this patient group
[Smith et al., 1997]. Our study identiﬁed a SNP, rs6585018:G>A,
located within the predicted promoter region of the PDCD4 gene
onchromosome10q24tobesigniﬁcantlyassociatedwithchildhood
asthma (P = 0.001). The largest GWAS for asthma to date did not
reportthepresentassociation;however,severeasthmainadultsand
children was not assessed separately [Moffatt et al., 2010]. A recent
GWAS examining severe asthma did not report any novel associa-
tions meeting genome-wide signiﬁcance [Wan et al., 2012]. Using
a P < 5 × 10
–5 as a threshold for genome-wide signiﬁcance, pre-
viously identiﬁed asthma-associated loci, ORMDL3/GSDML and
IL1RL1/IL18R1 were shown to be associated with asthma [Gudb-
jartssonetal.,2009;Moffattetal.,2010].Thestudyhoweverdidnot
stratify for different age groups and the mean age of asthma-onset
was 21 years.
Focusing our analysis in childhood asthma, we conducted ﬁne
mapping of the PDCD4 region revealing two further SNP asso-
ciations with severe asthma, rs34104444:G>A and rs1322997:C>A
(P = 0.004 and P = 0.002, respectively). For all three SNPs,
rs6585018:G>A, rs34104444:G>A and rs1322997:C>A belonging to
the same haplotype block, minor allele frequencies G, A, and C
respectively, were increased in asthmatics compared with the con-
trols. Interestingly, the same SNPs showing association with severe
asthma were also found to be associated with PDCD4 transcript
levels(http://www.sph.umich.edu/csg/liang/asthma),implyingthey
1136 HUMAN MUTATION, Vol. 34, No. 8, 1131–1139, 2013Figure 4. Supershift assays for PDCD4 SNP rs6585018:G>A using
10 μg of either A549, Daudi or Jurkat nuclear extracts. Lanes 1 and
8 contain only the hot probes rs6585018_A and rs6585018_G, respec-
tively. Lanes 2–7 include the rs6585018_A hot probe and lanes 9–14 the
rs6585018_Ghotprobe.A549extractsareincludedinlanes2and9with-
out the antibody and in lanes 3 and 10 with 0.3 ng of the MYB antibody.
Daudi extracts are included in lanes 4 and 11 without the antibody and
5 and 12 with 0.3 ng of the MYB antibody. Jurkat extracts are included
in lanes 6 and 13 without the antibody and in lanes 7 and 14 with 0.3 ng
of the MYB antibody. As expected the speciﬁc protein–DNA complex
is still observed in all cell lines tested. The addition of a MYB antibody
(lanes3,5,7,10,12,14)resultsinthelossoftheprotein–DNAcomplexes.
Figure5. ReporterassayresultscomparingbetweenJurkatcelllines
transfected with pGL3.rs6585018+A construct and pGL3.rs6585018+G
construct. The means fold increase ±SD of ﬁve independent transient
transfection experiments are shown. Paired t-test result was calcu-
lated comparing the mean luciferase activity of pGL3.rs6585018+A and
pGL3.rs6585018+G in each experiment (∗P < 0.02). Luciferase activity
wasnormalizedtoRenillaandexpressedrelativelytoemptyexpression
vector. Mean luciferase activity relative to empty vector was 1.31 (SD
0.25)forpGL3.rs6585018+Aand1.14(SD0.19)forpGL3.rs6585018+G.The
mean luminometer values of empty pGL3.promoter vector transfected
alone into Jurkat cell line were 3030 light units. A representation of
rs6585018+A and pGL3.rs6585018+G constructs is also provided.
have a functional role inﬂuencing the expression of the gene. The
asthma-associatedallele(Gallele)inrs6585018:G>Awasalsosignif-
icantly associated with higher IgE levels but not blood eosinophils
counts and lung function in the combined children group. Severe
asthmatic children have been generally associated more with atopic
symptoms compared with severe asthmatic adults [Miranda et al.,
2004; Wenzel, 2006].
We sought to explore these associations in an independent group
of asthmatic children from Germany. In this population group,
from all 14 tested SNPs in 10 genomic regions, PDCD4 SNPs
rs1407696:T>G and rs11195360:T>C were associated with total IgE
levels. The same SNPs were only borderline-associated with IgE in
the UK group of severe asthmatic children and controls, whereas
rs6585018:G>A was not associated with neither doctor-diagnosed
asthma nor total IgE in the replication group. These observations
may reﬂect real genetic heterogeneity between the two populations
or/and differences in phenotype deﬁnition. Indeed, asthma severity
deﬁnitioninthereplicationgroupdidnotfollowthesameguidelines
as the severe asthmatic group from the UK. Nevertheless, PDCD4
SNPs associations with the asthmatic status seen for the UK group
and IgE levels seen for both children groups from the UK and Ger-
manyindicatethatPDCD4isalocusofinterestforthedevelopment
of early onset severe asthma.
From bioinformatic analysis and EMSA results, SNP
rs6585018:G>A was found to affect binding ofthe transcription fac-
torMYBwiththeAallelehavingahigherafﬁnityforMYBcompared
with the allele G which is also the asthma risk allele in the present
study. The ﬁnding was conﬁrmed by reporter assays indicating that
MYB transcription factor exerts an allele-speciﬁc regulation of the
expression of PDCD4 gene. Of particular interest is the ﬁnding by
GWAS that SNPs in the MYB gene (MIM #189990) confer suscepti-
bility to eosinophil counts and asthma, providing further evidence
that the MYB/PDCD4 mechanism may be of general importance to
asthmatic inﬂammation [Gudbjartsson et al., 2009].
Myb transcription factor has been previously shown to induce
Pdcd4 expression in a chicken B cell line [Schlichter et al., 2001].
Using a B-lymphoid chicken cell line to disrupt Myb gene by ho-
mologous recombination resulting in Myb knock-out, Pdcd4 ex-
pression was diminished, providing additional evidence of the role
of the human MYB in the regulation of PDCD4 expression [Appl
and Klempnauer, 2002]. The presence of MYB regulatory elements
in PDCD4 promoter suggests that the human gene could be also
under MYB-transcriptional regulation. A recent study on the pro-
moterofPDCD4revealedstrongregulatoryelementsadjacenttothe
MYB binding site including rs6585018:G>A [Leupold et al., 2011].
PDCD4 is expressed in proliferating cells and protein levels are
modulated by IL-12 and IL-2 [Azzoni et al., 1998]. The protein in-
teracts with translation factor EIF4A through two MA-3 domains
inhibiting the initiation of translation [Yang et al., 2004; Yang et al.,
2003]. Interestingly, target mRNAs of PDCD4 include IL-4 and IL-
10[Hilliardetal.,2006].PDCD4actsasatranscriptionregulatorof
mRNA molecules such as the urokinase receptor u-PAR [Leupold
etal.,2007],which hasbeen foundtoinﬂuence theeosinophilicad-
hesioninasthmatics[Brooksetal.,2006].Recentstudieshaveshown
thatPDCD4takespartinthenegativeregulationofTLR4signaling,
aprominentpathwayinallergicasthma[Sheedyetal.,2010].Down-
regulationofPDCD4leadstotheestablishmentofaninﬂammatory
environment (IL-10, IL-6, TNF-α) [Yasuda et al., 2010], suggesting
a role in ﬁne-tuning inﬂammatory events. In the study by Sheedy
etal.,downregulationofPDCD4expressionwasmediatedviamiR-
21,amoleculefoundtobeup-regulatedinairwayinﬂammation[Lu
etal.,2009;Moschosetal.,2007].NegativeregulationofPDCD4by
miR-21 could also impact other pathophysiological characteristics
HUMAN MUTATION, Vol. 34, No. 8, 1131–1139, 2013 1137of asthma, like smooth muscle contractibility [Davis et al., 2008].
PDCD4 has been widely studied as anti-cancer therapeutic target
[Lankat-Buttgereit and Goke, 2009]; its role however as a transla-
tion inhibitor in inﬂammation, cell invasion and smooth muscle
contraction could be indicative of its implication in the expression
of the asthmatic phenotype.
The results from this study have shown that the putative
promoter-located PDCD4 SNP rs6585018:G>A is associated with
severe asthma in children and that it could inﬂuence the transcrip-
tion of the PDCD4 gene in an allele-dependent manner. Allele G
associated with severe asthma and higher total IgE levels leads to
less MYB binding and therefore lower PDCD4 expression as it is
evident by the functional analyses. Other studies using various cell
typeshaveshownthattheregulationofPDCD4expressioncanoccur
at many levels including transcriptional and translational and that
these mechanisms could be essential for a coordinated and con-
trolled regulation of the cellular protein levels [Lankat-Buttgereit
and Goke, 2009]. Importantly, the present study highlights the reg-
ulatory role of MYB in PDCD4 transcription, which needs to be
considered in future functional investigations of this molecule.
Our study has a number of limitations. First, the sample popu-
lation of severe asthmatic children is small (N = 116) explained by
the low frequency of this phenotype. However, our strategy enabled
us to investigate the extreme differentiated asthmatic phenotype
and control for the homogeneity of the selected cases, since they
wererecruitedfromthesamepediatricclinic.Ourstudyfocusedon
PDCD4SNPrs6585018:G>Aastheonesigniﬁcantlyassociatedwith
severe asthma and also predicted to have a functional role; how-
ever, due to the small size of our severe asthmatic children group,
we cannot fully disregard the rest of the GWAS hits as nonassoci-
ated with asthma. Second, the frequency of the risk allele G of SNP
rs6585018: G>A is low in the general population (CEU-HapMap;
MAF: 0.06), limiting the wider signiﬁcance of the ﬁnding. Nev-
ertheless, rare variants have been proven valuable in highlighting
novelmechanismsunderlyingdiseases[Weidingeretal.,2008].The
association was not reported in the largest asthma genetic study at
present including twenty thousands of cases and controls, possibly
because it included only a small number of severe asthmatic chil-
dren[Moffattetal.,2010].Animportantfollowingstepwouldbeto
further examine these ﬁndings in additional panels of severe asth-
matics, with subphenotypes of lung function measurements, blood
eosinophilsandmostimportantlyatopicstatustoconﬁrmtheroleof
PDCD4SNPsassociationsandclarifythefunctionalrelevanceofthe
molecule.
In conclusion, this study combining a genetic analysis in well-
deﬁnedpopulationofsevereasthmaticsandcontrols,incorporating
functional approaches reports that PDCD4 locus is associated with
severe asthma and IgE levels, whereas SNP rs6585018:G>A exerts
a regulatory effect on PDCD4 expression. We therefore propose
that the PDCD4 protein and MYB-dependent regulation would be
worthwhile for further investigation of its role in asthma-related
mechanisms.
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